IMMUTEP LIMITED - AMER

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

19 نوفمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Immutep Publishes AIPAC, TACTI-002 and TACTI-003 Trial Posters at SITC with Positive New Data for LAG-3 Therapy, Eftilagimod Alpha

15 نوفمبر 2021 07:00:03 بحسب Nasdaq GlobeNewswire

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Fusion Protein, in Combination with a PD-1 Pathway Inhibitor

15 نوفمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts for SITC 2021 Annual Meeting & AIPAC Global Webcast Details

09 نوفمبر 2021 07:05:00 بحسب Nasdaq GlobeNewswire

Immutep Reports Improved and Statistically Significant Survival Benefit for Three Key Patient Groups in Final Phase IIb AIPAC Study Results in Metastatic Breast Cancer

09 نوفمبر 2021 07:00:04 بحسب Nasdaq GlobeNewswire

Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a Chemotherapy Agent

02 نوفمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

29 أكتوبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Immutep Quarterly Activities Report & Appendix 4C

28 أكتوبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Immutep to Present Phase II TACTI-002 Data at SITC 2021

01 أكتوبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

29 سبتمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Immutep to Present at Healthcare Investor Conferences

28 سبتمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

21 سبتمبر 2021 07:38:03 بحسب Nasdaq GlobeNewswire

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

01 سبتمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

31 أغسطس 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

27 أغسطس 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

05 أغسطس 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

13 يوليو 2021 07:00:03 بحسب Nasdaq GlobeNewswire

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

06 يوليو 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

21 يونيو 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

21 يونيو 2021 07:00:00 بحسب Nasdaq GlobeNewswire